Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer
Authors:
Open Access
- 24 November 2015
- journal article
- research article
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 320
Abstract
The objective of this study was to investigate the safety and long-term clinical effect of intraperitoneal implantation of sustained-release 5-fluorouracil in patients with advanced colorectal cancer during radical resection. A total of 202 patients with advanced colorectal cancer undergoing radical operations were randomly divided into an experimental group (98 cases, intraoperative intraperitoneal implantation of sustained-release 5-fluorouracil 600 mg as local chemotherapy) and a control group (104 cases, without local chemotherapy). The clinical data of the two groups was compared including toxicity, complications, local recurrence rate, distant metastasis, disease-free survival, and 1-, 3-, and 5-year survival rates. Both groups of patients were followed up for more than 5 years, the longest follow-up time was 7.5 years. Bone marrow suppression, hepato-renal function, postoperative anastomotic leakage, pelvic effusion, incision infection, the incidence of intestinal obstruction, venting time, and hospital stay after operation (days) between two groups had no statistical significant difference. Locoregional recurrence and liver metastasis rate were decreased significantly in experimental group (P = 0.04 and 0.04). Extensive peritoneal metastasis and other organ metastasis rates had no significant difference between two groups. In the experimental group, 1-, 3-, and 5-year survival rates were higher than in the control group (95.92 vs 87.50 %, 77.55 vs 64.42 %, and 56.12 vs 40.38 %), which had significant difference. Disease-free survival (DFS) of the experimental group was higher than that of the control group (χ 2 = 5.00, P = 0.025). Intraperitoneal implantation of sustained-release 5-fluorouracil is safe for advanced colorectal cancer during radical resection, which can reduce locoregional recurrence rate and liver metastasis rate. The long-term efficacy was reliable, and long-term survival and disease-free survival rate can be improved.Keywords
This publication has 25 references indexed in Scilit:
- Experimental study on sustained-release 5-Fluorouracil implantation in canine peritoneum and para-aortic abdominalis.Asian Pacific Journal of Cancer Prevention, 2014
- Can Capecitabine be used Instead of Concurrent Bolus 5-FU in Postoperative Chemoradiotherapy for Gastric Adenocarcinoma?Asian Pacific Journal of Cancer Prevention, 2013
- Down-Regulation of Claudin-18 Is Associated with the Proliferative and Invasive Potential of Gastric Cancer at the Invasive FrontPLOS ONE, 2013
- Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesotheliomaSurgery, 2013
- Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected databaseBMC Cancer, 2013
- Correlation of SATB1 overexpression with the progression of human rectal cancerInternational Journal of Colorectal Disease, 2011
- Clinical Outcome and Clinicopathological Characteristics of Recurrence after Laparoscopic Gastrectomy for Advanced Gastric CancerDigestion, 2011
- Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.2007
- Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II–III colorectal cancer: a multicentre randomised controlled phase III trialThe Lancet Oncology, 2005
- Detection of Carcinoembryonic Antigen‐expressing Free Tumor Cells in Peritoneal Washes from Patients with Gastric Carcinoma by Polymerase Chain ReactionJapanese Journal of Cancer Research, 1997